Inotiv, Inc. (NOTV)
USD 3.95
(-28.83%)
USD 3.95
(-28.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -26.5 Million USD | 206.53% |
| 2022 | -273.42 Million USD | -579.57% |
| 2021 | 15.36 Million USD | 355.97% |
| 2020 | 1.02 Million USD | -2016.67% |
| 2019 | 2.57 Million USD | -820.0% |
| 2018 | 1.87 Million USD | -98.44% |
| 2017 | 2.96 Million USD | 162.19% |
| 2016 | -1.28 Million USD | -767.64% |
| 2015 | 1.71 Million USD | -86.65% |
| 2014 | 1.02 Million USD | 176.46% |
| 2013 | 2.55 Million USD | 133.76% |
| 2012 | -3.39 Million USD | -172.46% |
| 2011 | 3.43 Million USD | 949.39% |
| 2010 | 327 Thousand USD | 122.01% |
| 2009 | -1.95 Million USD | -125.42% |
| 2008 | 5.8 Million USD | -1.89% |
| 2007 | 2.39 Million USD | 290.91% |
| 2006 | 366 Thousand USD | -67.54% |
| 2005 | 4.72 Million USD | 29.23% |
| 2004 | 3.66 Million USD | 20.51% |
| 2003 | 3.48 Million USD | -15.28% |
| 2002 | 3.66 Million USD | -32.11% |
| 2001 | 5.25 Million USD | 891.55% |
| 2000 | 444.1 Thousand USD | -74.91% |
| 1999 | 2.2 Million USD | 40.0% |
| 1998 | 1.6 Million USD | -6.25% |
| 1997 | 1.6 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -24.04 Million USD | -419.85% |
| 2024 Q3 | -982 Thousand USD | 75.12% |
| 2024 Q1 | 9.24 Million USD | -54.73% |
| 2023 Q2 | 11.41 Million USD | 188.96% |
| 2023 Q3 | 22.63 Million USD | 98.38% |
| 2023 Q4 | 18.64 Million USD | -17.64% |
| 2023 Q1 | -12.82 Million USD | -240.5% |
| 2023 FY | - USD | 206.53% |
| 2022 Q3 | 21.22 Million USD | 50.1% |
| 2022 Q1 | -87.97 Million USD | -994.75% |
| 2022 Q2 | 14.14 Million USD | 116.08% |
| 2022 FY | - USD | -579.57% |
| 2022 Q4 | 9.12 Million USD | -57.0% |
| 2021 Q1 | 14 Thousand USD | 101.02% |
| 2021 Q3 | -1.7 Million USD | -397.66% |
| 2021 FY | - USD | 355.97% |
| 2021 Q4 | 9.83 Million USD | 677.67% |
| 2021 Q2 | -342 Thousand USD | -2542.86% |
| 2020 Q1 | -286 Thousand USD | -156.3% |
| 2020 Q4 | -1.36 Million USD | -328.93% |
| 2020 Q3 | 598 Thousand USD | -20.9% |
| 2020 FY | - USD | -2016.67% |
| 2020 Q2 | 756 Thousand USD | 364.34% |
| 2019 Q1 | 42 Thousand USD | 156.76% |
| 2019 Q4 | 508 Thousand USD | 304.84% |
| 2019 FY | - USD | -820.0% |
| 2019 Q3 | -248 Thousand USD | -250.3% |
| 2019 Q2 | 165 Thousand USD | 292.86% |
| 2018 Q3 | 347 Thousand USD | -29.47% |
| 2018 Q1 | 415 Thousand USD | 41.64% |
| 2018 FY | - USD | -98.44% |
| 2018 Q4 | -74 Thousand USD | -121.33% |
| 2018 Q2 | 492 Thousand USD | 18.55% |
| 2017 Q3 | 782 Thousand USD | -23.33% |
| 2017 Q1 | 491 Thousand USD | 154.02% |
| 2017 FY | - USD | 162.19% |
| 2017 Q2 | 1.02 Million USD | 107.74% |
| 2017 Q4 | 293 Thousand USD | -62.53% |
| 2016 FY | - USD | -767.64% |
| 2016 Q2 | 70 Thousand USD | 137.63% |
| 2016 Q1 | -186 Thousand USD | 76.49% |
| 2016 Q3 | -7000.00 USD | -110.0% |
| 2016 Q4 | -909 Thousand USD | -12885.71% |
| 2015 Q1 | 144 Thousand USD | 271.43% |
| 2015 Q2 | 380 Thousand USD | 163.89% |
| 2015 Q3 | 1.25 Million USD | 229.74% |
| 2015 Q4 | -791 Thousand USD | -163.13% |
| 2015 FY | - USD | -86.65% |
| 2014 FY | - USD | 176.46% |
| 2014 Q4 | -84 Thousand USD | -112.86% |
| 2014 Q3 | 653 Thousand USD | 29.05% |
| 2014 Q2 | 506 Thousand USD | 9.29% |
| 2014 Q1 | 463 Thousand USD | 367.68% |
| 2013 FY | - USD | 133.76% |
| 2013 Q4 | 99 Thousand USD | -88.27% |
| 2013 Q3 | 844 Thousand USD | 96.74% |
| 2013 Q2 | 429 Thousand USD | -44.79% |
| 2013 Q1 | 777 Thousand USD | 108.31% |
| 2012 Q1 | -751 Thousand USD | -521.91% |
| 2012 Q3 | 662 Thousand USD | 163.23% |
| 2012 FY | - USD | -172.46% |
| 2012 Q2 | -1.04 Million USD | -39.41% |
| 2012 Q4 | 373 Thousand USD | -43.66% |
| 2011 Q2 | 1.16 Million USD | 9.46% |
| 2011 Q4 | 178 Thousand USD | -82.31% |
| 2011 Q1 | 1.06 Million USD | 106.18% |
| 2011 FY | - USD | 949.39% |
| 2011 Q3 | 1 Million USD | -13.94% |
| 2010 Q1 | -640 Thousand USD | -267.1% |
| 2010 Q2 | -681 Thousand USD | -6.41% |
| 2010 Q3 | 1.12 Million USD | 265.64% |
| 2010 FY | - USD | 122.01% |
| 2010 Q4 | 518 Thousand USD | -54.08% |
| 2009 Q4 | 383 Thousand USD | -32.69% |
| 2009 FY | - USD | -125.42% |
| 2009 Q1 | -892 Thousand USD | -634.13% |
| 2009 Q2 | -1.54 Million USD | -72.65% |
| 2009 Q3 | 569 Thousand USD | 136.95% |
| 2008 Q3 | 1.82 Million USD | 110.88% |
| 2008 Q4 | 167 Thousand USD | -90.83% |
| 2008 Q1 | 1.02 Million USD | 11.71% |
| 2008 Q2 | 864 Thousand USD | -15.38% |
| 2008 FY | - USD | -1.89% |
| 2007 Q2 | 1.31 Million USD | -23.51% |
| 2007 Q4 | 914 Thousand USD | -54.16% |
| 2007 Q3 | 1.99 Million USD | 51.29% |
| 2007 FY | - USD | 290.91% |
| 2007 Q1 | 1.72 Million USD | 397.22% |
| 2006 Q1 | 37 Thousand USD | -97.42% |
| 2006 Q2 | 1.91 Million USD | 5086.49% |
| 2006 Q3 | -912 Thousand USD | -147.52% |
| 2006 Q4 | -579.7 Thousand USD | 36.44% |
| 2006 FY | - USD | -67.54% |
| 2005 Q1 | 1.65 Million USD | 522.93% |
| 2005 Q2 | -265 Thousand USD | -115.99% |
| 2005 Q3 | 1.85 Million USD | 799.25% |
| 2005 Q4 | 1.43 Million USD | -22.65% |
| 2005 FY | - USD | 29.23% |
| 2004 Q3 | 2.38 Million USD | 871.84% |
| 2004 Q1 | 729 Thousand USD | 254.47% |
| 2004 FY | - USD | 20.51% |
| 2004 Q4 | 266 Thousand USD | -88.83% |
| 2004 Q2 | 245 Thousand USD | -66.39% |
| 2003 Q2 | 439 Thousand USD | -57.41% |
| 2003 Q1 | 1.03 Million USD | 67.44% |
| 2003 FY | - USD | -15.28% |
| 2003 Q4 | 522.69 Thousand USD | -85.45% |
| 2003 Q3 | 854 Thousand USD | 241.3% |
| 2002 Q3 | 820 Thousand USD | -36.51% |
| 2002 Q4 | 650.73 Thousand USD | -28.06% |
| 2002 FY | - USD | -32.11% |
| 2002 Q2 | 1.28 Million USD | 42.81% |
| 2002 Q1 | 916 Thousand USD | -38.04% |
| 2001 Q4 | 1.44 Million USD | 3.7% |
| 2001 FY | - USD | 891.55% |
| 2001 Q3 | 1.4 Million USD | -5.97% |
| 2001 Q2 | 1.47 Million USD | 58.39% |
| 2001 Q1 | 931 Thousand USD | 29.73% |
| 2000 Q4 | 636.1 Thousand USD | 220.04% |
| 2000 Q2 | -245 Thousand USD | -133.0% |
| 2000 Q1 | -100 Thousand USD | -111.11% |
| 2000 Q3 | 225 Thousand USD | 196.14% |
| 2000 FY | - USD | -74.91% |
| 1999 Q3 | 400 Thousand USD | -33.33% |
| 1999 Q2 | 600 Thousand USD | 100.0% |
| 1999 Q1 | 300 Thousand USD | 50.0% |
| 1999 FY | - USD | 40.0% |
| 1999 Q4 | 900 Thousand USD | 125.0% |
| 1998 Q4 | 200 Thousand USD | -50.0% |
| 1998 Q1 | 500 Thousand USD | 525.0% |
| 1998 Q2 | 600 Thousand USD | 20.0% |
| 1998 FY | - USD | -6.25% |
| 1998 Q3 | 400 Thousand USD | -33.33% |
| 1997 FY | - USD | 0.0% |
| 1997 Q4 | 80 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 87.591% |
| Prenetics Global Limited | -47.89 Million USD | 44.659% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -1471.191% |
| CareDx, Inc | -89.65 Million USD | 70.436% |
| Exact Sciences Corporation | 41.87 Million USD | 163.296% |
| Exagen Inc. | -19.15 Million USD | -38.391% |
| Guardant Health, Inc. | -433.3 Million USD | 93.883% |
| Biodesix, Inc. | -37.1 Million USD | 28.561% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -966.571% |
| Precipio, Inc. | -4.31 Million USD | -513.849% |
| iSpecimen Inc. | -9.1 Million USD | -191.156% |
| Natera, Inc. | -383.27 Million USD | 93.084% |
| Aspira Women's Health Inc. | -16.49 Million USD | -60.73% |
| Standard BioTools Inc. | -54.45 Million USD | 51.327% |
| 23andMe Holding Co. | -291.87 Million USD | 90.919% |
| Castle Biosciences, Inc. | -45.02 Million USD | 41.129% |
| Personalis, Inc. | -96.8 Million USD | 72.62% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 77.454% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -176.362% |
| OpGen, Inc. | -29.51 Million USD | 10.183% |
| T2 Biosystems, Inc. | -43.87 Million USD | 39.587% |
| Myriad Genetics, Inc. | -67.8 Million USD | 60.906% |
| ICON Public Limited Company | 1.63 Billion USD | 101.624% |
| NeoGenomics, Inc. | -17.6 Million USD | -50.542% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -1471.191% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 102.177% |
| RadNet, Inc. | 292.78 Million USD | 109.053% |
| MDxHealth SA | -30.46 Million USD | 13.004% |
| Psychemedics Corporation | -251 Thousand USD | -10460.159% |
| Illumina, Inc. | -608 Million USD | 95.64% |
| Check-Cap Ltd. | -17.64 Million USD | -50.184% |
| Twist Bioscience Corporation | -176.7 Million USD | 85.0% |
| DarioHealth Corp. | -53.49 Million USD | 50.451% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 43.062% |
| Sera Prognostics, Inc. | -35.28 Million USD | 24.885% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -170.889% |
| OPKO Health, Inc. | -65.51 Million USD | 59.543% |
| Medpace Holdings, Inc. | 363.15 Million USD | 107.299% |
| Neogen Corporation | 182.59 Million USD | 114.516% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -200.839% |
| Prenetics Global Limited | -47.89 Million USD | 44.659% |
| Mainz Biomed B.V. | -25.01 Million USD | -5.977% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -247.424% |
| Trinity Biotech plc | -24.09 Million USD | -9.993% |
| Neuronetics, Inc. | -22.75 Million USD | -16.464% |
| Sotera Health Company | 514.14 Million USD | 105.155% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -247.424% |